Link Cell Therapies Adds $30M, Expands Series A to $90M

Link Cell Therapies has raised an additional $30 million, increasing its Series A round to a total of $90 million, according to a report by FinSMEs.

The upsize confirms continued investor appetite for the cell therapy sector, where biotech developers have relied on extended private rounds to fund costly clinical pipelines despite a broader tightening in life-sciences venture funding.

A $90 million Series A places Link Cell Therapies among the better-capitalized early-stage players in its field. The fresh $30 million tranche gives the company additional runway without forcing it to return to market for a full new round — a structure several biotechs have adopted recently to preserve valuations amid tougher financing conditions.

FinSMEs, which first reported the raise, did not disclose the investors participating in the extension or the valuation attached to the round. The company has not publicly detailed the specific programs the new capital will support.

Cell therapy development remains one of the most capital-intensive categories in biopharma. Manufacturing complexity, long clinical timelines and rigorous regulatory requirements mean companies in the space typically burn through nine-figure sums before reaching commercialization. A larger Series A gives Link Cell Therapies room to advance its pipeline through the expensive early clinical stages.

The raise also signals that specialized healthcare investors remain willing to concentrate capital in select cell therapy bets, even as overall biotech funding has cooled from its 2021 peak. Rounds of this size at the Series A stage generally indicate backing from syndicates with deep reserves and a multi-year commitment to the technology platform.

With $90 million now committed, Link Cell Therapies joins the cohort of private cell therapy developers positioned to push candidates into and through human trials without near-term dependence on public markets.